CSL与礼来公司达成独家许可协议，授予克拉扎单抗开发和商业化的某些权利，预付1亿美元、潜在里程碑付款以及基于销售的特许权使用费

2026-02-18 17:02

Under the terms of the agreement, CSL will retain exclusive rights to develop and commercialise clazakizumab for the prevention of cardiovascular events in patients with end-stage kidney disease (ESKD).
CSL is advancing the ongoing POSIBIL 6ESKD Phase 3 clinical trial (NCT05485961), which is evaluating the efficacy and safety of clazakizumab in patients with ESKD on dialysis at risk for major cardiovascular events.
Under the terms of the agreement, CSL will retain exclusive rights to develop and commercialise clazakizumab for the prevention of cardiovascular events in patients with ESKD.
Lilly will explore the development, global regulatory approval, and commercialisation of clazakizumab in additional indications. CSL will receive an upfront payment of $100 million and be eligible to receive potential clinical, regulatory and commercial milestone payments, as well as royalties on global net sales